Deanna is a seasoned biotech executive with unparalleled experience in global business, corporate development and strategic planning.

She previously led business development for Shire’s rare disease unit, where she and her team identified and evaluated new business opportunities and negotiated and executed more than 40 licenses, mergers, acquisitions and other transactions in five years, including a $4.2 billion acquisition of ViroPharma. Prior to joining Shire, Deanna was vice president of business development at Agenus Inc. and at Coley Pharmaceutical Group.

Deanna sits on the board of directors for Tecogen, Inc. (TGEN) and has previously served on boards at Armagen, American DG Energy (ADGE), the Massachusetts Biotechnology Association, the Boston chapter of the Healthcare Businesswomen’s Association and the Boston BioPharma Executive Council.